CTOs on the Move

Genentech

www.genetech.com

 
Genentech, Inc., is a biotechnology corporation which became a subsidiary of Roche in 2009.
  • Number of Employees: 5K-10K
  • Annual Revenue: $0-1 Million
  • www.genetech.com
  • 1, DNA Way
    South San Francisco, CA USA 94080
  • Phone: 650.225.1000

Executives

Name Title Contact Details

Similar Companies

Tioma Therapeutics

Tioma is an immuno-oncology company developing anti-CD47 antibodies for the treatment of solid and hematologic cancers. Our functionally diverse antibodies represent a new class of checkpoint inhibitors that harness both the adaptive and innate immune responses.

Atalanta Therapeutics

Atalanta was created to address the urgent global need for interventions to treat neurodegenerative diseases. Our founders` groundbreaking discoveries in RNA interference offer a powerful therapeutic approach to halt diseases at their source.

Biosplice Therapeutics

Biosplice is developing first-in-class, small-molecule therapeutics based on pioneering science of alternative pre-mRNA splicing.

Enzyvant

Enzyvant is also advancing the development of RVT-802, an investigational tissue-based biologic therapy for the potential treatment of primary immune deficiency associated with complete DiGeorge Syndrome. RVT-802 has been granted orphan drug designation, Breakthrough Therapy designation, Regenerative Medicine Advanced Therapy designation, and pediatric rare disease designation by the U.S. Food and Drug Administration. Enzyvant anticipates a potential BLA filing for RVT-802 in the first half of 2018. Enzyvant plans to develop treatments for additional rare diseases with high unmet need.

Regenexx

The Regenexx Procedures are a family of non-surgical stem cell and blood platelet treatments for common injuries and degenerative joint conditions, such as osteoarthritis and avascular necrosis. These stem cell procedures utilize a patient’s own stem c...